Core Viewpoint - The enzyme-linked immunosorbent assay (ELISA) industry in China is experiencing rapid growth, driven by government support, advancements in optical technology, and the application of nanomaterials, leading to increased sensitivity and precision in testing [1][6]. Industry Overview - ELISA is a specialized instrument for enzyme-linked immunosorbent assays, widely used in medical diagnostics, drug development, and food safety monitoring due to its efficiency, accuracy, and ease of use [3][6]. - The market for ELISA in China saw a significant increase in the first quarter of 2025, with a total of 285 units awarded, amounting to over 60 million yuan, representing a year-on-year increase of 721.9% in quantity and 519.6% in value compared to the first quarter of 2024 [1][6]. Industry Chain - The upstream of the ELISA industry includes raw materials such as metals, plastics, optical components, and electronic components, which directly affect the quality and stability of the instruments [4][5]. - The midstream involves manufacturers integrating raw materials and technology to produce ELISA products that meet market demands [4]. - The downstream applications span biochemistry, biomedicine, and environmental monitoring, with ELISA playing a crucial role in disease diagnosis and environmental pollution assessment [5]. Market Trends - The demand for ELISA is shifting towards lower-tier markets, driven by policy support and the upgrading of grassroots medical services, which is expected to become a core growth engine for the industry [12]. - Technological advancements are enhancing the performance of ELISA instruments, with a focus on increasing sensitivity, speed, and automation, including the emergence of smart ELISA devices utilizing AI and big data [13]. - Miniaturization and portability of ELISA instruments are anticipated to be significant trends, facilitating use in remote areas and field testing [14]. - Globalization and regionalization are both influencing the ELISA market, with companies expanding into international markets while also customizing products to meet local demands [15]. Competitive Landscape - The Chinese ELISA market is characterized by a fragmented competitive landscape, with numerous domestic and international manufacturers competing on quality, price, and service [6]. - Key players in the industry include Mindray Medical (300760), Antu Bio (603658), and others, which are enhancing their market share through continuous innovation and product development [1][6].

Investment Rating - The report gives a "Recommended" rating for the innovative drug sector, highlighting the potential for value reassessment as companies transition from generic to innovative products [45]. Core Insights - The innovative drug industry is expected to shift from quantity logic to quality logic, emphasizing the importance of differentiated products and internationalization of pipelines [10]. - The medical device market is experiencing a recovery in bidding volumes, particularly in imaging equipment, and is benefiting from government subsidies for home medical devices [10][50]. - The report indicates a significant decline in the retail scale of physical pharmacies, with a cumulative scale of 395.2 billion yuan from January to August 2025, down 2.2% year-on-year [16]. Market Analysis Innovative Drugs - The number of innovative products in the pipeline has increased significantly, with expectations of launching five new innovative products annually over the next three years [45]. - The revenue share from innovative products is projected to exceed 50% by 2025, indicating a successful transition to a more innovative product structure [45]. Medical Devices - The imaging equipment market is recovering, with a notable increase in procurement activities expected in late 2024 [50]. - Home medical devices are benefiting from government subsidies, which are expected to drive growth in this segment [50]. Retail Pharmacy - The retail scale of physical pharmacies has been under pressure due to policy constraints and increased competition, leading to a decline in profitability [16]. - The cumulative scale of retail pharmacies in July and August 2025 was 991 billion yuan, reflecting a 2.5% year-on-year decline [16]. Product Categories - All product categories in the pharmacy sector showed negative growth from January to August 2025, with the largest decline seen in health products, which dropped over 17% [20]. - The pharmaceutical market saw a cumulative scale of 321.7 billion yuan, down 1.2% year-on-year, with specific declines attributed to reduced demand for respiratory medications [24]. Traditional Chinese Medicine - The market for traditional Chinese medicine is experiencing a decline, with a cumulative scale of 302 billion yuan, down 4.7% year-on-year [25]. - The retail scale of traditional Chinese medicine showed signs of stabilization in August, with a slight month-on-month increase [25]. Health Products - The health product market saw a cumulative scale of 149 billion yuan, down 17.7% year-on-year, although there was a slight recovery in August [33]. Chemical Drugs - The top 20 chemical drug categories accounted for 78.0% of sales in July, with notable growth in categories such as hemostatic drugs and immunosuppressants [37][40]. - The market share for chemical drugs in August increased to 78.5%, with several categories showing positive year-on-year growth [38][40].

Autobio Diagnostics CO., Ltd. 安图生物 2025 年第二次临时股东大会会议材料 郑州安图生物工程股份有限公司 郑州安图生物工程股份有限公司 2025 年第二次临时股东大会会议材料 （股票代码：603658） 河南 · 郑州 二○二五年十一月 Autobio Diagnostics CO., Ltd. 安图生物 2025 年第二次临时股东大会会议材料 郑州安图生物工程股份有限公司 郑州安图生物工程股份有限公司 2025 年第二次临时股东大会目录 一、程序文件 二、提交股东大会审议的议案 1. 会议议程 2. 会议须知 1.《关于修订<公司章程>暨取消监事会、设置职工代表董事的议案》 2.00 《关于修订并制定公司内部治理制度的议案》 2.01 《股东会议事规则》 2.02 《董事会议事规则》 2.03 《独立董事工作制度》 2.04 《关联交易管理制度》 2.05 《对外担保管理制度》 2.06 《重大投资和交易决策制度》 2.07 《募集资金管理办法》 2.08 《累积投票制实施细则》 Autobio Diagnostics CO., Ltd. 安图生物 2025 年第二次临时股 ...

Autobio Diagnostics CO., Ltd. 安图生物 2025 年第二次临时股东大会会议材料 郑州安图生物工程股份有限公司 郑州安图生物工程股份有限公司 2025 年第二次临时股东大会会议材料 （股票代码：603658） 河南 · 郑州 二○二五年十一月 Autobio Diagnostics CO., Ltd. 安图生物 2025 年第二次临时股东大会会议材料 郑州安图生物工程股份有限公司 郑州安图生物工程股份有限公司 2025 年第二次临时股东大会目录 一、程序文件 二、提交股东大会审议的议案 1. 会议议程 2. 会议须知 1.《关于修订<公司章程>暨取消监事会、设置职工代表董事的议案》 2.00 《关于修订并制定公司内部治理制度的议案》 2.01 《股东会议事规则》 2.02 《董事会议事规则》 2.03 《独立董事工作制度》 2.04 《关联交易管理制度》 2.05 《对外担保管理制度》 2.06 《重大投资和交易决策制度》 2.07 《募集资金管理办法》 2.08 《累积投票制实施细则》 Autobio Diagnostics CO., Ltd. 安图生物 2025 年第二次临时股 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 股东大会有关情况 1. 原股东大会的类型和届次： 2025年第二次临时股东大会 证券代码：603658 证券简称：安图生物 公告编号：2025-075 郑州安图生物工程股份有限公司 关于2025年第二次临时股东大会通知的更正 补充公告 2. 原股东大会召开日期：2025 年 11 月 14 日 3. 原股东大会股权登记日： | 股份类别 | 股票代码 | 股票简称 | 股权登记日 | | --- | --- | --- | --- | | Ａ股 | 603658 | 安图生物 | 2025/11/7 | 二、 更正补充事项涉及的具体内容和原因 郑州安图生物工程股份有限公司（以下简称"公司"）于 2025 年 10 月 30 日 在上海证券交易所网站（www.sse.com.cn）披露了《安图生物关于召开 2025 年 第二次临时股东大会的通知》（公告编号：2025-073 号）。经公司审核后发现：原 股东大会通知"二、会议审议事项"和"附件 1：授权委托书"中需逐项表决的议 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future investment returns [5][3]. Core Insights - The company experienced a revenue decline of 7.48% year-on-year in the first three quarters of 2025, with total revenue reaching 3.127 billion yuan. The net profit attributable to shareholders also decreased by 10.11% to 860 million yuan [1][2]. - In Q3 2025, the company reported a revenue of 1.067 billion yuan, down 9.04% year-on-year, and a net profit of 289 million yuan, down 14.30% year-on-year [1][2]. - The company has achieved multiple product registrations, including innovative testing kits and automated instruments, showcasing its commitment to research and development despite a 19.91% decrease in R&D expenses [2][3]. Financial Performance Summary - Revenue and profit forecasts for 2025-2027 are as follows: - 2025E Revenue: 4.622 billion yuan, Net Profit: 1.264 billion yuan - 2026E Revenue: 5.214 billion yuan, Net Profit: 1.473 billion yuan - 2027E Revenue: 5.928 billion yuan, Net Profit: 1.722 billion yuan [4][9]. - The company’s P/E ratios are projected to decrease from 17 in 2025 to 13 in 2027, indicating potential value appreciation [4][12]. Market Strategy and Collaborations - The company is deepening domestic market collaborations with strategic partners to expand distribution channels and regional resources, while also pursuing international partnerships to enhance its global footprint [3][2]. - The company has actively contributed to public health initiatives, such as providing high-throughput sequencing platforms for disease control efforts [3].

Summary of the Conference Call on Antu Biology's Q3 Performance Company Overview - **Company**: Antu Biology - **Industry**: Biotechnology and Medical Diagnostics Key Points and Arguments Financial Performance - **Q3 Revenue**: Approximately 3.127 billion CNY, with a year-on-year decline of 1.5% [2][3] - **Segment Performance**: - **Enzyme-linked Immunosorbent Assay (ELISA)**: Revenue of 1.766 billion CNY, down 7.86% year-on-year [2] - **Microbial Testing Reagents**: Revenue of 271 million CNY, down 1.08% [3] - **Nucleic Acid Testing Reagents**: Revenue of 25.957 million CNY, down 2.57% [3] - **Asset Instruments**: Revenue of 287 million CNY, up 17.45% [3] - **Export Revenue**: 277 million CNY, up 38.35% [3] Industry Dynamics - **Policy Impact**: The industry is significantly affected by policies such as centralized procurement and the potential implementation of a national unified pricing directory [7][8] - **Market Recovery**: The company believes that the market is nearing a bottom, with slight improvements expected in the coming years, although growth will be slow due to pressures on medical insurance payments [8][9] - **Price Adjustments**: The company anticipates that price adjustments will occur post-implementation of the tumor testing centralized procurement policy, with expected adjustments in the single-digit percentage range [12][36] Equipment Installation and Sales - **Installation Numbers**: - 600-speed machines: 559 units installed [4] - 200-speed machines: 400 units installed [4] - **Sales Strategy**: Adjustments were made to sales targets for agents due to high initial expectations, which were not met [10] Export Growth - **Export Performance**: Significant growth in exports, particularly in instruments, with Q3 international sales reaching approximately 73 million USD, a year-on-year increase of over 130% [14][15] - **Key Markets**: Growth noted in countries like Russia, Mexico, and Brazil, with India remaining a primary market [16][17] Competitive Landscape - **Domestic vs. Imported Products**: The company is positioned to benefit from the shift towards domestic products as hospitals increasingly opt for local suppliers due to pricing pressures on imports [38][39] - **Market Share**: The company expects to capture a larger market share as imported brands struggle with pricing and compliance issues [39] Future Outlook - **Long-term Strategy**: The company aims for a 50% annual growth target in international markets, emphasizing local sales and service [26] - **Product Development**: Continued investment in product development and market expansion is planned, particularly in the sequencing business [22][23] Challenges - **Regulatory Delays**: Delays in obtaining necessary certifications for new products may hinder growth in the sequencing segment [22][23] - **Price Competition**: The company faces challenges from aggressive pricing strategies in the market, particularly from larger competitors [28][30] Conclusion - Antu Biology is navigating a challenging environment marked by regulatory changes and competitive pressures. However, the company is optimistic about gradual recovery and growth, particularly in the domestic market, as it adapts its strategies to align with evolving industry dynamics.

郑州安图生物工程股份有限公司 股东会议事规则 郑州安图生物工程股份有限公司 股东会议事规则 （2025 年 10 月修订） 第一章 总 则 第一条 为进一步明确郑州安图生物工程股份有限公司（以下简称"公司"）股东会的 职责权限，规范股东会运作，保证股东会会议程序和决议的有效、合法，更好地维护全体股 东的合法权益，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共 和国证券法》（以下简称《证券法》）《上市公司治理准则》《上市公司股东会规则》《上 海证券交易所股票上市规则》等有关法律、法规、规范性文件和《郑州安图生物工程股份有 限公司章程》（以下简称"《公司章程》"）的规定，制定本规则。 第二条 公司股东会的召集、提案、通知、召开等事项适用本规则。 第三条 公司应当严格按照法律、行政法规、《上市公司股东会规则》及《公司章程》 的相关规定召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当勤勉尽责， 确保股东会正常召开和依法行使职权。 第四条 公司股东会由全体股东组成。股东会是公司的权力机构，应当在《公司法》和 《公司章程》规定的范围内行使职权。 ...

第二条 公司交易与关联交易行为应当合法合规，不得隐瞒关联关系，不得通过将关联 交易非关联化规避相关审议程序和信息披露义务。相关交易不得存在导致或者可能导致上市 公司出现被控股股东、实际控制人及其他关联人非经营性资金占用、为关联人违规提供担保 或者其他被关联人侵占利益的情形。 第二章 关联人 郑州安图生物工程股份有限公司 关联交易管理制度 郑州安图生物工程股份有限公司 关联交易管理制度 （2025 年 10 月修订） 第一章 总 则 第一条 为规范郑州安图生物工程股份有限公司（以下简称"公司"）的关联交易行为， 保证公司关联交易决策行为的公允性，提高公司规范运作水平，保护公司和全体股东的合法 权益，特别是保护中小投资者的合法权益，根据《中华人民共和国公司法》（以下简称"《公 司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上市公司信息披露管 理办法》《上海证券交易所股票上市规则》（以下简称"《股票上市规则》"）《上海证券 交易所上市公司自律监管指引第 5 号——交易与关联交易》以及等法律、法规和规范性文件 及《公司章程》的有关规定，制定本制度。 第三条 关联交易的定义：公司、控股子公司及控制的其他 ...

郑州安图生物工程股份有限公司 会计师事务所选聘制度 郑州安图生物工程股份有限公司 会计师事务所选聘制度 第二条 本制度所称选聘会计师事务所，是指公司根据相关法律法规要求，聘任会计师 事务所对财务会计报告发表审计意见、出具审计报告的行为。公司聘任会计师事务所从事除 财务会计报告审计之外的其他法定审计业务的，可以比照本制度执行。 第三条 公司聘用或解聘会计师事务所，应当由审计委员会审议同意后，提交董事会审 议，并由股东会决定。 第四条 公司控股股东、实际控制人不得在公司董事会、股东会审议前，向公司指定会 计师事务所，也不得干预审计委员会独立履行选聘职责。 第二章 会计师事务所执业要求 第五条 公司聘任的会计师事务所应当具备下列条件： （一）具有完全的民事行为能力，具备国家行业主管部门和中国证监会规定的开展证券、 期货业务相关业务资格； （二）具有固定的工作场所、健全的组织机构和有效的内部管理和控制制度； （三）具有良好的执业质量记录、职业道德记录和信誉，认真执行有关财务审计的法律、 法规和政策规定； （2025 年 10 月修定） 第一章 总 则 第一条 为规范郑州安图生物工程股份有限公司（以下简称"公司"）选聘 ...